Current
Research Interests
My interest is the pharmacogenetics of Phase II metabolic enzymes including
the glutathione S-transferase, sulfotransferase and methyltransferase
families. My current research is the characterisation of novel glutathione
transferases including understanding the functional consequences of genetic
variation in protein coding and regulatory
regions and how this relates to human disease (including cancer, nephrotic
syndromes, peripheral neuropathies, diabetes, adverse drug reactions and
arsenic metabolism).
Currently I am working on:
1. A knockout mouse model for GSTK1 to understand the function of this
novel mitochondrial GST; this mouse has a nephrotic syndrome (damaged
kidneys) and is highly sensistive to paracetamol toxicity.
2. Regulation of human GSTK1 to try to understand if changes in the expression
of this gene contribute to similar human diseases.
3. Understanding how a novel GST-like protein (called GDAP1) alters mitochondrial
morphology.
4. Determining how genetic changes in GDAP1 cause Charcot-Marie-Tooth
disease (a peripheral neuropathy) 5. Regulation of human GSTO1 (arsenic
metabolism) to understand the influence of polymorphisms in the promoter
region.
Potential Projects
If you are interested in doing a third year undergraduate research placement
or Honours project in our laboratory, please contact me, Alison.Shield@anu.edu.au
Potential projects are available in the following areas:
1. How do members of the ets transcription factor family control GSTK1
expression?
2. Do kidney specific transcription factors control GSTK1 expression in
the glomeruli?
3. How do polymorphisms in the GDAP1 promoter influence gene expression?
4. How does GDAP1 interacts with other members of the fission/fusion machinary?
5. Does glutathione interacts with GDAP1 to influence mitochondrial morphology?
6. Does arsenic cause changes in GSTO1 expression?
Education | Academic
Appointments | Professional Associations | Publications
Tertiary Education
2006 Certificate in Clinical Research - Mayo Clinic and Graduate School
2000 Doctor of Philosophy (Health Sciences) - Flinders University of South
Australia "The role of aryl sulfotransferases and glutathione S-transferase
M1 in human toxicity and genotoxicity".
2000 Graduate Diploma in Sciences Communication - Central Queensland University
1994 Bachelor of Biotechnology (Honours) - Flinders University of South
Australia
Academic Appointments
Dec 2003 - present: NHMRC Australian Biomedical (Peter Doherty) Fellowship
Molecular Genetics Group, John Curtin School of Medical Research, Australian
National University
Aug 2002 - Sept 2003: Postdoctoral Research Fellow in Mayo Cancer Genetics
and Epidemiology Training Program
Dept. Molecular Pharmacology & Experiemental Therapeutics, Mayo
Clinic USA
Dec 2000 - Aug 2002: Postdoctoral Research Fellow in Pharmacology
Dept. Molecular Pharmacology & Experiemental Therapeutics, Mayo
Clinic USA
Professional Associations
International Society for the Study of Xenobiotics
American Association of Cancer Research
Australian Society of Medical Research
Australian Society for Biochemistry and Molecular Biology Australian
Society for Clinical and Experimental Pharmacology and Toxicology
Biochemical Society
Publications
Peer Reviewed Publications
Shield AJ, Murray TP, and Board PG (2006) Functional characterisation
of ganglioside-induced differentiation-associated protein 1 as a glutathione
transferase. Biochem Biophys Res Commun. 347(4):859-66.
Shield AJ, Thomae BA, Eckloff BW, Weiben ED, Weinshilboum RM. (2004) Human
catechol O-methyltransferase (COMT): Gene resequencing and functional
characterisation of polymorphisms. Molecular Psychiatry 9:151-160.
Shield AJ, Webb GC and Sanderson BJS (2004) Recombinant models for assessing
the role of GSTM1 in styrene-7,8-oxide mutagenicity. Toxicology 195: 61ˆ68.
Shield AJ and Sanderson BJS (2001) Role of Glutathione-S-Transferase Mu
(GSTM1) in Styrene-7,8-oxide Toxicity and Mutagenicity. Environmental
and Molecular Mutagenesis 37: 285-289.
Sanderson BJS and Shield AJ (1996) Mutagenic damage to mammalian cells
by therapeutic alkylating agents. Mutation Research 355: 41-57.
Published Abstracts
Coggan M, Matthaei KI, Blackburn AC, Cappello JY, Shield AJ, Board PG
and Dahlstrom JE (2006) The generation and characterization of
glutathione transferase Kappa deficient mice. Drug Met Rev 38(3): 124.
Shield AJ, Robinson A, Warren A, and Board PG (2004) Glutathione S-transferase
Kappa: localisation studies in mammalian cells using immunogold labelling
and electron microscopy. Drug Metabolism Reviews 36(suppl 1): 169
Shield AJ, Janet E. Olson, Robert A. Vierkant, V. Shane Pankratz, Zachary
S. Fredericksen, William R. Taylor, Dennis J. O'Kane, Thomas A. Sellers,
Richard M. Weinshilboum. (2003) COMT polymorphisms and breast cancer risk
in the Minnesota Breast Cancer Family Study. Proc AACR Volume 44 (2):
5450
Shield AJ and Weinshilboum RM. (2002) Human Catechol O-MethylTransferase
(COMT) polymorphisms: Functional genomic studies. Drug Metabolism Reviews
24 (suppl 1): 153.
Shield AJ, Thomae BA, Eckloff BW, Weiben ED, Weinshilboum RM (2001) Human
Catechol O-MethylTransferase (COMT): Gene resequencing and functional
characterisation of polymorphisms. Drug Metabolism Reviews 33(suppl 1):
198.
Shield AJ and Sanderson BJS (1998) Vanillin: sulfotransferase substrate
or inhibitor? ISSX Proc. 13:116.
Shield AJ and Sanderson BJS (1997) The role of glutathione S-transferase
mu (GSTM1) in styrene oxide toxicity and genotoxicity. ISSX Proc. 12:79.
Sanderson BJS, Binns AM and Shield, AJ (1997) Toxicity of contaminated
and bioremediated soil to human and microbial cells. ISSX Proc. 12:77.
Shield AJ, Zhu X, McManus ME, and Veronese ME (1995) Baculoviral-mediated
expression of a human monamine-sulfating phenol sulfotransferase. ISSX
Proc. 8:364.
|
